Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7161-7166

  Greiner, Jochen ^a   Bullinger, Lars ^a   Guinn, Barbara Ann ^b   Döhner, Hartmut ^a   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Rayne Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CD135 ANTIGEN; LEUKEMIA ANTIGEN; M PHASE PHOSPHOPROTEIN 11; MYELOBLASTIN; NUCLEIC ACID BINDING PROTEIN; ONCOFETAL ANTIGEN; PROTEIN BAGE; PROTEIN BCL 2; PROTEIN PRAME; PROTEIN RHAMM; PROTEIN TYROSINE KINASE; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; WT1 PROTEIN; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DEMETHYLATION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LEUKEMIA CELL; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION;

EID: 58149359323     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1102     Document Type: Review

References (87)

1. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
2. Andersen MH, Svane IM, Kvistborg P, et al. Immunogenicity of Bcl-2 in patients with cancer. Blood 2005;105:728-34.
3. Siegel S, Wagner A, Kabelitz D, et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 2003;102:4416-23.
4. Pillai MM, Iwata M, Awaya N, Graf L, Torok-Storb B. Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood 2006;107:3520-6.
5. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
6. Vissers JL, DeVries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59:5554-9.
7. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005;106:938-45.
8. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006;108:4109-17.
9. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
10. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675-81.
11. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003;111:639-47.
12. Schmidt SM, Schag K, Müller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-6.
13. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
14. Greiner J, Ringhoffer M, Taniguchi M, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002;30:1029-35.
15. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99:3272-9.
16. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-90.
17. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 2003;331-49.
18. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111:236-42.
19. Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008;111:1357-65.
20. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006;91:1653-61.
21. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002;138:89-91.
22. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
23. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
24. + cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006;107:205-12.
25. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-25.
26. Yanada M, Terakura S, Yokozawa T, et al. Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004;45:1803-8.
27. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-94.
28. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-63.
29. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-6.
30. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-65.
31. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004;10:3737-44.
32. Guinn BA, Bullinger L, Thomas NS, Mills KI, Greiner J. SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol 2007;140:250-1.
33. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
34. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125-31.
35. Daneshbod Y, Amirghofran Z, Tabei SZ. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 2005;52:109-14.
36. Cong XL, Han ZC. Survivin and leukemia. Int J Hematol 2004;80:232-8.
37. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dorken B, Tamm I. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006;119:1291-7.
38. waf1 by proteinase-3, amyeloid-specific serine protease, potentiates cell proliferation. J Biol Chem 2002;277:47338-47.
39. Pederzoli M, Kantari C, Gausson V, Moriceau S, Witko-Sarsat V. Proteinase-3 induces procaspase-3 activation in the absence of apoptosis: potential role of this compartmentalized activation of membrane-associated procaspase-3 in neutrophils. J Immunol 2005;174:6381-90.
40. Hall CL, Yang B, Yang X, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995;82:19-28.
41. Wang C, Thor AD, Moore DH II, et al. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998;4:567-76.
42. Greiner J, Ringhoffer M, Taniguchi M, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004;108:704-11.
43. Kip1. Blood 2004;103:1059-68.
44. Denniss FA, Breslin A, Ingram W, Hardwick NR, Mufti GJ, Guinn BA. The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. Br J Haematol 2007;138:668-9.
45. Shoji W, Inoue T, Yamamoto T, Obinata M. MIDA1, a protein associated with Id, regulates cell growth. J Biol Chem 1995;270:24818-25.
46. Resto VA, Caballero OL, Buta MR, et al. A putative oncogenic role for MPP11 in head and neck squamous cell cancer. Cancer Res 2000;60:5529-35.
47. Okada H, Attanucci J, Giezeman-Smits KM, et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res 2001;61:2625-31.
48. Hundley HA, Walter W, Bairstow S, Craig EA. Human Mpp11 J protein: ribosome-tethered molecular chaperones are ubiquitous. Science 2005;308:1032-4.
49. Grunau C, Sanchez C, Ehrlich M, et al. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 2005;43:11-24.
50. Guinn BA, Mohamedali A, Thomas NS, Mills KI. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 2007;56:943-57.
51. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 2007;92:153-62.
52. Guinn BA, Gilkes AF, Woodward E, et al. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005;333:703-13.
53. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007;13:1089-97.
54. b2a2 construct. Blood 1999;94:1038-45.
55. + T-cell epitopes. Leukemia 2006;20:1738-50.
56. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037-42.
57. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005;365:657-62.
58. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007;21:2287-95.
59. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996;33:480-7.
60. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9.
61. G250/MN by HIF-1á in clear cell renal cell carcinoma. Oncogene 2004;23:5624-31.
62. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
63. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835-47.
64. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
65. Gu W, Chen Z, Hu S, Shen H, Qiu G, Cao X. Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. Haematologica 2005;90:403-5.
66. Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR, Loeb DM. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 2006;107:4695-702.
67. Gaidzik V, Habdank M, Moschny S, et al. Clinical Impact of WT1 mutations in the context of other molecular markers in cytogenetically normal acute myeloid leukemia (AML): a study of the German-Austrian AML study group (AMLSG). Blood 2007;110:364.
68. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998;91:2961-8.
69. Nishida S, Hosen N, Shirakata T, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2006;107:3303-12.
70. Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD, Sukumar S. Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 2002;277:19627-32.
71. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett 2004;564:9-13.
72. Warner JK, Wang JC, Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 2005;19:1794-805.
73. Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005;90:307-16.
74. Haining WN, Neuberg DS, Keczkemethy HL, et al. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood 2005;106:1749-54.
75. Wendelbo O, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud O. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 2004;53:740-7.
76. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
77. Vollmer M, Li L, Schmitt A, et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 2003;120:1000-8.
78. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001;97:256-63.
79. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 2006;55:830-40.
80. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol 2003;131:82-9.
81. + tumor cells in B chronic lymphocytic leukemia. Blood 1998;91:4273-81.
82. Bruserud O, Ulvestad E. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels. Cancer Immunol Immunother 2000;49:377-87.
83. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-45.
84. + T regulatory cells. Blood 2007;109:2871-7.
85. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
86. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007;19:217-23.
87. Ono M, Yaguchi H, Ohkura N, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007;446:685-9.